# A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors

> **NCT02298387** · PHASE1 · COMPLETED · sponsor: **OncoMed Pharmaceuticals, Inc.** · enrollment: 71 (actual)

## Conditions studied

- Advanced Solid Tumor Malignancies

## Interventions

- **DRUG:** OMP-305B83

## Key facts

- **NCT ID:** NCT02298387
- **Lead sponsor:** OncoMed Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-22
- **Primary completion:** 2017-05-23
- **Final completion:** 2017-09-08
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2020-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02298387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02298387, "A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02298387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*